However, a large cohort study conducted on 8471 patients with RA, ankylosing spondylitis, psoriatic arthritis, psoriasis, and IBD showed that anti-TNF-α therapy does not increase the occurrence of ILDs among patients with autoimmune diseases when compared to non-biologic treatments [61]. This evidence concerns the gene TNF and inflammatory bowel disease.